Group One Trading, L.P. Contrafect Corp Transaction History

Group One Trading, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$0.09 - $0.19 $3,012 - $6,359	-33,471 Reduced 40.54%	49,100 $4,000
Q3 2022 Nov 09, 2022	BUY	$0.18 - $3.51 $14,862 - $289,824	82,571 New	82,571 $14,000
Q1 2022 May 12, 2022	SELL	$2.26 - $3.84 $11,767 - $19,994	-5,207 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.47 - $4.14 $7,970 - $13,359	-3,227 Reduced 38.26%	5,207 $14,000
Q3 2021 Nov 12, 2021	SELL	$3.19 - $4.43 $7,971 - $11,070	-2,499 Reduced 22.86%	8,434 $34,000

Q2 2021 Aug 10, 2021	SELL	$3.58 - $4.9 $4,872 - $6,668	-1,361 Reduced 11.07%	10,933 $48,000
Q1 2021 May 12, 2021	BUY	$4.46 - $6.68 $54,831 - $82,123	12,294 New	12,294 $59,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.